Anthony Aiudi, PharmD
Anthony has been part of the investment team at Morningside Technology Advisory since 2020. He has experience providing operational and managerial oversight to early-stage biotechnology companies. Anthony serves on the boards of several biotechnology companies across a broad spectrum of therapeutic areas, including Fount Bio, Biothea, and Cyted. He has also facilitated company creation, completed multiple financings for private companies, and provided operational support for portfolio companies. Anthony completed a Fellowship in Clinical Research at Cubist Pharmaceuticals and Northeastern University, where he was also adjunct faculty. He later was a senior clinical research scientist at Merck & Co. From late 2015-2020, he was a director at Stealth BioTherapeutics, where he led the clinical development for numerous rare disease programs through their global Phase 3 program and supported the company through its IPO. Anthony received his Pharm.D. and MBA from the University of Rhode Island and an M.S. in finance from Northeastern University.
Andreas Reiff, MD
Andreas has extensive experience in medical leadership, with a focus on advancing treatments for autoimmune and inflammatory diseases. Prior to joining Neutrolis, Andreas served as Rheumatology Division Head at Children's Hospital Los Angeles (CHLA), University of Southern California; as Senior VP (Immunology & Inflammation) at Parexel, and founded TheraKine Ltd. At Neutrolis, he oversees clinical development and medical strategy, to ensure the highest standards of medical ethics, safety and efficacy. Andreas guides the company through clinical trials, regulatory submissions, and medical affairs, dedicated to bringing transformative treatments to market.
Ralph Lambalot, PhD
Ralph has 25+ years of experience developing manufacturing processes and analytical methods in support of commercial, clinical and preclinical biotherapeutic products. Prior to joining Neutrolis, Ralph was VP of Biologics Operations Science & Technology at AbbVie overseeing development and commercial manufacturing of Humira® and previously held senior scientist roles at Pfizer and BASF. Ralph is a bioorganic chemist and trained at Brown University and Harvard Medical School. At Neutrolis, Ralph leads chemistry manufacturing and controls (CMC).
Ken Olivier Jr., PhD
Ken has 22+ years of experience in drug development and regulatory strategy and is skilled in toxicology, regulatory affairs, and quality assurance. Ken is an experienced drug development veteran with a history of developing therapies in the biotechnology and pharmaceutical industry. Ken previously held positions in Regeneron, Biogen, GSK, and Merimak Pharmaceuticals. Ken received his Bachelors in Toxicology from the University of Louisiana at Monroe and PhD in Veterinary Biomedical and Clinical Sciences from Oklahoma State University. At Neutrolis, Ken oversees product development and assists with non-clinical and regulatory strategies.
Ghazaleh Gouya Lechner, MD
Ghazaleh has 20+ years of clinical research experience and is an Associate Professor in Internal Medicine and board certified in internal medicine, cardiology, and clinical pharmacology. Previously, Ghazaleh lead a research group at the phase I Unite of the Medical University Vienna and was Medical Director at a global CRO. She has been involved in the development and approval of numerous products and has led product strategy and protocol development by identifying and documenting the best ways to help patients. Ghazaleh and her clinical team at Gouya Insights lead Neutrolis’ clinical strategy and operations.
